Wegovy, Mounjaro or Rybelsus - which medication is right for you

Mounjaro (tirzepatide), Wegovy (semaglutide) and Rybelsus (oral semaglutide) are the three GLP-1 medications we prescribe for weight management. Wegovy and Mounjaro are once-weekly injections; Rybelsus is a daily tablet. All three will work for the patients they are right for, and all three sit on our menu as first-line options rather than first-and-second-best.

A note on the regulatory framing. Wegovy and Mounjaro carry a UK weight-management licence from the MHRA. Rybelsus is MHRA-licensed for type 2 diabetes and is prescribed off-label for weight management in private practice. Off-label prescribing is a normal, legal and commonly-used part of UK medicine where the evidence supports it; for oral semaglutide and weight management, it does. We explain this in your consultation if you are starting on Rybelsus, because you should know it.

The choice between the three depends on factors we work through together in your first consultation. This article explains what is actually different, and how we make the call.

Effectiveness

This is the question everyone asks first. In the largest head-to-head trials (SURPASS-2, SURMOUNT, STEP and PIONEER programmes):

Mounjaro at its maximum 15mg dose produces an average weight loss of around 22.5 percent of starting body weight after 72 weeks of treatment.

Wegovy at 2.4mg produces an average weight loss of around 15 percent over the same period. The newer 7.2mg Wegovy dose (MHRA-approved January 2026) achieves 20.7 percent.

Rybelsus at its maximum 14mg daily dose produces an average weight loss of around 4-5 percent over a year. Newer trial data on higher 25mg and 50mg oral doses show 13-15 percent, but those higher-dose oral formulations are not yet UK-licensed for weight management.

The Rybelsus number is genuinely smaller, and we are honest about it. The reason is absorption: only about 0.4-1 percent of each oral dose survives stomach acid and reaches the bloodstream. The injectables deliver the medication directly. For modest weight goals or for maintenance after injectable treatment, Rybelsus is a real option; for substantial weight loss as the primary goal, the injectables are the higher-yield choice.

Side effect profile

All three share the same family of side effects, dominated by gastrointestinal upset during titration. Nausea, constipation, and occasional vomiting affect most patients at some point in the first twelve weeks and then settle.

There are some differences that matter for specific patients.

Wegovy tends to have marginally more reports of nausea at comparable effectiveness doses.

Mounjaro tends to have marginally more reports of mild diarrhoea or loose stool.

Rybelsus has a milder GI profile overall, partly because the dose reaching the bloodstream is lower; nausea is reported by a smaller proportion of patients than on Wegovy, and it is usually shorter-lived.

All three share the small but real risks of gallstone disease, pancreatitis, and thyroid C-cell tumours (the last of which has only been demonstrated in rats, not in humans, but is still included as a theoretical contraindication in patients with a personal or family history of medullary thyroid cancer or MEN2).

If you have a sensitive stomach or a history of reflux, the choice between the three is often decided by which side effect profile you would rather work with.

Cost

UK private pricing varies significantly by provider. The underlying list prices from the manufacturers matter:

Mounjaro (Eli Lilly) list price rose sharply in September 2025. The 15mg maintenance dose now lists at around £330 per four-week pen before the provider's margin and fees.

Wegovy (Novo Nordisk) pricing has been more stable. The 2.4mg dose typically runs £220-260 per month and the newer 7.2mg dose around £290-320.

Rybelsus 14mg lists at around £130-150 per month at retail. The lower price reflects the lower dose-effect ratio rather than a discount.

At LoveMyLife your monthly care subscription includes your medication from our own pharmacy. You pay the same monthly fee regardless of which of the three you are on or which dose you are at. Dose escalations inside a calendar month do not trigger additional charges.

Availability and supply

The injectables have been subject to intermittent supply disruption over the last two years, particularly at starting doses. Our in-house pharmacy gives us advance visibility of wholesale supply. If one medication is difficult to source we will tell you honestly and switch you or start you on another, rather than leaving you waiting for three weeks. Rybelsus supply has been more stable.

Cardiovascular evidence

This matters if you have existing cardiovascular risk factors.

Semaglutide (the active ingredient in both Wegovy and Rybelsus) has specific evidence from the SELECT trial showing cardiovascular benefit in people with pre-existing cardiovascular disease and overweight or obesity. The MHRA licence for Wegovy now includes a cardiovascular benefit indication. Rybelsus inherits the same active ingredient and a strong body of cardiovascular safety data from its type 2 diabetes use.

Tirzepatide's equivalent cardiovascular outcome trial (SURPASS-CVOT) is ongoing. Early signals are consistent with benefit, but the formal cardiovascular benefit indication has not yet been granted in the UK.

If you have had a heart attack, stroke, or documented coronary artery disease, a semaglutide-based option (Wegovy or Rybelsus) is currently the more conservative evidence-based choice.

Diabetes and pre-diabetes

If you have type 2 diabetes or significant pre-diabetes:

Mounjaro has the stronger glycaemic effect. HbA1c reductions on Mounjaro are typically 1.5-2.0 percent at maintenance dose, compared with 1.0-1.5 percent for semaglutide.

Wegovy and Rybelsus both deliver semaglutide; the HbA1c effect of injectable semaglutide is slightly stronger than oral semaglutide at currently licensed doses.

If your main goal is weight loss but your HbA1c is also in the 42-50 mmol/mol pre-diabetic range, Mounjaro gives you the dual benefit, with Wegovy a close second.

How you want to take the medication

This is the question that matters most after effectiveness, and the one patients often arrive without having thought about.

Wegovy and Mounjaro: one self-administered injection a week, taken on the same day each week, any time of day, with or without food. Most patients find injections far less difficult than they expected; the pen needles are very small.

Rybelsus: one tablet every morning, on an empty stomach with no more than 120ml of plain water, at least 30 minutes before eating or drinking anything else. That window must be protected every day. If your morning routine includes coffee before brain-on, Rybelsus is hard.

A weekly injection demands less of your day-to-day routine than a daily tablet with a fasting window. A daily tablet demands no injection. Different lives suit different rhythms.

How we make the decision with you

In your first consultation we work through:

Your weight-loss goal and starting BMI.

Your cardiovascular risk (established disease or risk factors).

Your HbA1c.

Your personal and family medical history (thyroid, pancreatitis, gallstones).

Your tolerance for an injection and your morning routine.

Your preferences and any prior experience with these medications.

Your budget and whether you are paying for all twelve months up front or month by month.

In most cases more than one of the three is reasonable. Our common starting points: for patients with BMI over 30 and no specific contraindication, Mounjaro at 2.5mg with planned escalation; for patients with established cardiovascular disease, Wegovy; for patients who genuinely cannot face injection or who have a moderate weight-loss goal, Rybelsus. For patients who have tried one and not tolerated it, we switch to one of the others.

You are not locked in

Switching between the three during treatment is straightforward. If you start on Mounjaro and want to switch to Wegovy or Rybelsus after three months, we do that at your next review with no additional assessment charge. All three come from our own pharmacy, so the switch happens in days, not weeks.

[Begin your consultation](/services/weight-management/prepare) with our weight management doctors.

Ready to start?

If this article has made you think medication might help, the next step is a short consultation with one of our weight-management doctors.

Begin your assessment at this link. Online in 30 minutes, or in person at Westfield London.